An effect comparison of teriparatide and bisphosphonate on posterior lumbar interbody fusion in patients with osteoporosis: a prospective cohort study and preliminary data.

Cho PG, Ji GY, Shin DA, Ha Y, Yoon DH, Kim KN

European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society10 Dec 2015Cited by 66 (Europe PMC)

PMID26661639DOI10.1007/s00586-015-4342-yPepBankPUB-26661639

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In osteoporotic spinal surgery patients, alternating teriparatide and alendronate was associated with shorter fusion time than alendronate alone.
In plain wordsIn patients with osteoporosis, the alternating teriparatide and alendronate regimen was linked to shorter spinal fusion time than alendronate alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTime to bone fusion
Study
n = 47
Comparator
Sodium alendronate
Outcome group
Bone and joint · Musculoskeletal
Measurements
Mean bone fusion time
6 months
alternating teriparatide and alendronate
Mean bone fusion time
10.4 months
alendronate alone
Source sentences
Summary
The average period of bone fusion was 6.0 ± 4.8 months in the teriparatide group but 10.4 ± 7.2 months in the bisphosphonate group.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-seven osteoporotic patients underwent PLIF with pedicle screw fixation for degenerative lumbar stenosis and instability.
Summary · context
The teriparatide group (n = 23) was injected subcutaneously with teriparatide (20 μg daily) for 3-month cycles alternating with 3-month periods of oral sodium alendronate for 12 months.
Summary · context
The bisphosphonate group (n = 24) was administered oral sodium alendronate (91.37 mg/week) for ≥1 year.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2666163901
02HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In osteoporotic spinal surgery patients, fusion rates at 6 months were higher with alternating teriparatide and alendronate than alendronate alone.
In plain wordsIn patients with osteoporosis, the alternating teriparatide and alendronate regimen was linked to higher spinal fusion rates than alendronate alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFusion rate at 6 months
Study
n = 47
Comparator
Sodium alendronate
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The bone fusion rate in the teriparatide group was higher than that in the bisphosphonate group at 6 months; however, there was no difference 12 and 24 months after surgery.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-seven osteoporotic patients underwent PLIF with pedicle screw fixation for degenerative lumbar stenosis and instability.
Summary · context
The teriparatide group (n = 23) was injected subcutaneously with teriparatide (20 μg daily) for 3-month cycles alternating with 3-month periods of oral sodium alendronate for 12 months.
Summary · context
The bisphosphonate group (n = 24) was administered oral sodium alendronate (91.37 mg/week) for ≥1 year.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2666163902
03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In osteoporotic spinal surgery patients, fusion rates did not differ between alternating teriparatide/alendronate and alendronate alone at 12 and 24 months.
In plain wordsIn patients with osteoporosis, spinal fusion rates did not differ between the alternating regimen and alendronate at 12 and 24 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFusion rate at 12 and 24 months
Study
n = 47
Comparator
Sodium alendronate
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The bone fusion rate in the teriparatide group was higher than that in the bisphosphonate group at 6 months; however, there was no difference 12 and 24 months after surgery.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-seven osteoporotic patients underwent PLIF with pedicle screw fixation for degenerative lumbar stenosis and instability.
Summary · context
The teriparatide group (n = 23) was injected subcutaneously with teriparatide (20 μg daily) for 3-month cycles alternating with 3-month periods of oral sodium alendronate for 12 months.
Summary · context
The bisphosphonate group (n = 24) was administered oral sodium alendronate (91.37 mg/week) for ≥1 year.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2666163903
04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In osteoporotic spinal surgery patients, pain scores did not differ significantly between alternating teriparatide/alendronate and alendronate alone.
In plain wordsIn patients with osteoporosis, pain scores did not differ significantly between the alternating regimen and alendronate alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changePain scores
Study
n = 47
Comparator
Sodium alendronate
Outcome group
Pain · Musculoskeletal
Source sentences
Summary
Pain scores and ODI were not significantly different between groups.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-seven osteoporotic patients underwent PLIF with pedicle screw fixation for degenerative lumbar stenosis and instability.
Summary · context
The teriparatide group (n = 23) was injected subcutaneously with teriparatide (20 μg daily) for 3-month cycles alternating with 3-month periods of oral sodium alendronate for 12 months.
Summary · context
The bisphosphonate group (n = 24) was administered oral sodium alendronate (91.37 mg/week) for ≥1 year.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2666163904
05HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In osteoporotic spinal surgery patients, ODI did not differ significantly between alternating teriparatide/alendronate and alendronate alone.
In plain wordsIn patients with osteoporosis, disability scores did not differ significantly between the alternating regimen and alendronate alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeOswestry disability index
Study
n = 47
Comparator
Sodium alendronate
Outcome group
Exercise and physical function · Musculoskeletal
Source sentences
Summary
Pain scores and ODI were not significantly different between groups.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-seven osteoporotic patients underwent PLIF with pedicle screw fixation for degenerative lumbar stenosis and instability.
Summary · context
The teriparatide group (n = 23) was injected subcutaneously with teriparatide (20 μg daily) for 3-month cycles alternating with 3-month periods of oral sodium alendronate for 12 months.
Summary · context
The bisphosphonate group (n = 24) was administered oral sodium alendronate (91.37 mg/week) for ≥1 year.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2666163905
06HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In osteoporotic spinal surgery patients, BMD improvement at 2 years was greater with alternating teriparatide and alendronate than alendronate alone.
In plain wordsIn patients with osteoporosis, the alternating teriparatide and alendronate regimen was linked to greater bone density improvement than alendronate alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBMD at 2 years
Study
n = 47
Comparator
Sodium alendronate
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
BMD scores in the teriparatide group were significantly improved compared with the bisphosphonate group 2 years after surgery.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-seven osteoporotic patients underwent PLIF with pedicle screw fixation for degenerative lumbar stenosis and instability.
Summary · context
The teriparatide group (n = 23) was injected subcutaneously with teriparatide (20 μg daily) for 3-month cycles alternating with 3-month periods of oral sodium alendronate for 12 months.
Summary · context
The bisphosphonate group (n = 24) was administered oral sodium alendronate (91.37 mg/week) for ≥1 year.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2666163906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.